HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Feb. 14, 2012 (HealthDay News) -- Using brain scans, researchers were able to monitor mental decline over a two-year period in people without dementia and even predict the disorder before it happened, according to a new report.
Scientists may one day be able to use brain scans to track the effectiveness of medications designed to treat Alzheimer's disease. This brain-robbing disorder currently has no cure, and its progression cannot be halted by medication either.
The scans can detect a chemical marker developed by the researchers that binds to plaques -- a kind of brain gunk -- and "tangles," which are both linked to Alzheimer's disease. The investigators tested the effectiveness of the method on 43 healthy study participants, whose average age was 64. Nearly half of the volunteers had a form of memory loss called "mild cognitive impairment."
The study findings are published in the February issue of the Archives of Neurology.
"We are finding that this may be a useful neuroimaging marker that can detect changes early, before symptoms appear, and it may be helpful in tracking changes in the brain over time," study author Dr. Gary Small, a professor of psychiatry at the Semel Institute for Neuroscience and Human Behavior at the University of California, Los Angeles, said in a university news release.
The researchers found that they were able to link scan results to mental decline after two years, and were even able to use findings from the initial scans to predict some kinds of brain decline in the participants two years later.
The next step is to use the scans to study the effectiveness of medications designed to treat brain aging, and therapies used to try to delay or prevent Alzheimer's disease, Small explained in the news release.
In response to the question of whether the scans could be useful for patients right now, Catherine Roe, a research assistant professor of neurology and Alzheimer's specialist at Washington University in St. Louis, who was not involved with the study, pointed out that doctors have other ways to detect mental decline, and there's still no preventive treatment for Alzheimer's disease.
Yet, "although I don't think this technology is ready to be applied in doctors' offices right now, I think it would be useful clinically in helping to determine what the underlying cause of the [mental] decline is, whether it's Alzheimer's or something else," Roe said.
For more about Alzheimer's disease, visit the U.S. National Library of Medicine.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on September 22, 2022